Get App
Download App Scanner
Scan to Download
Advertisement

UPL Delivers Seventh Straight Quarter Of Growth, But Systematix Remains Cautious — Check Revised Target Price

UPL's Q1 revenue growth was supported by disciplined pricing actions, favorable currency movements and growth across segments, while profitability improved on the back of contribution margin expansion, better product mix and lower finance costs, adds the brokerage.

UPL Delivers Seventh Straight Quarter Of Growth, But Systematix Remains Cautious — Check Revised Target Price
UPL's revenue increased 10.5% YoY to Rs 10,180 crore, broadly in line with Systematix' estimate of Rs 10,140 crore, driven by 3% pricing growth and favourable currency movements, partly offset by a 3% decline in volumes.
(Photo: NDTV Profit/ AI generated image)
STOCKS IN THIS STORY
UPL Ltd.
--

NDTV Profit's special research section collates quality and in-depth equity and economy research reports from across India's top brokerages, asset managers and research agencies. These reports offer NDTV Profit's subscribers an opportunity to expand their understanding of companies, sectors and the economy.

Systematix Report

According to the brokerage firm Systematix, UPL Ltd. delivered a resilient start to FY27, with earnings broadly in line with expectations and continued improvement in profitability despite a challenging operating environment.

However, near-term growth remains constrained by weather-related volume pressures, uncertain global demand and geopolitical risks. 

Systematix maintains its Hold rating with updated price target of Rs 670 implying 5.7x FY28E Ebitda.

UPL Result highlights:

Revenue increased 10.5% YoY to Rs 10,180 crore, broadly in line with brokerage's estimate of Rs 10,140 crore, driven by 3% pricing growth and favourable currency movements, partly offset by a 3% decline in volumes. Ebitda increased 11.3% YoY to Rs 1,450 crore, 5% above our estimate of Rs 1,420 crore.

The company reported a PAT of Rs 10 crore, compared with a loss of Rs 90 crore in Q1 FY26, driven by Ebitda growth, lower net finance costs and favourable net exchange differences.

Click on the attachment to read the full report:

Systematix Upl Q1.pdf
VIEW DOCUMENT

ALSO READ: Glenmark Pharma's India-US Growth Story Intact, Says Motilal Oswal, Maintaining 'Buy' — Check Target Price

DISCLAIMER

This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories — On NDTV Profit.

To continue reading this story
You must be an existing Premium User

Newsletters

Update Email
to get newsletters straight to your inbox
⚠️ Add your Email ID to receive Newsletters
Note: You will be signed up automatically after adding email

News for You

Set as Trusted Source
on Google Search
Add NDTV Profit As Google Preferred Source
Loading PDF...
Listen to the latest songs, only on JioSaavn.com